Recent Finacing
Recent Raise
Retension Pharmaceuticals is a clinical-stage biopharma developing RTN-001, an oral selective PDE5 inhibitor with preferential cardiovascular distribution and a modified-release formulation, advancing to a Phase 2b hypertension trial.
